Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

Enrolling by invitation

Phase N/A Results N/A

Summary of Purpose

The goal of this study is to preliminarily determine/estimate feasibility and whether frequent and early conivaptan use, at a dose currently determined to be safe (i.e., 40mg/day), is safe and well-tolerated in patients with cerebral edema from intracerebral hemorrhage (ICH) and pressure (ICP). A further goal is to preliminarily estimate whether conivaptan at this same dose can reduce cerebral edema (CE) in these...

Read More →

Trial Milestones

The following dates are available for this trial. Trial information last updated on 24 April 2018.

1 Jan 2017 14 Dec 2016 1 Jan 2020 1 Jan 2020 1 Apr 2018 Unavailable
Start Date First Received 1st Completion Completion Verification Results

Trial Basics


Conditions See All


Trial Design

Not available